MURANO update: MRD, biological subsets & safety analysis

MURANO update: MRD, biological subsets & safety analysis

VJHemOnc

1 year
24 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
MURANO (NCT02005471) is a Phase III randomized trial comparing the efficacy of venetoclax plus rituximab vs. standard chemoimmunotherapy of bendamustine plus rituximab in relapsed/refractory chronic lymphocytic leukemia (CLL). John Seymour, MBBS, FRACP, PhD, of the Peter MacCallum Cancer Center, Victoria, Australia, presented results from this trial at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. Here, he discusses the benefits of venetoclax plus rituximab in patients with 17p deletions or TP53 mutations, who do not respond well to chemoimmunotherapy. He also speaks about the positive safety data from the trial, as well as the promising number of patients who have achieved sustained measurable residual disease (MRD) negativity.
Up Next Autoplay